BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 17615271)

  • 21. Long-term correction of hemophilia A mice following lentiviral mediated delivery of an optimized canine factor VIII gene.
    Staber JM; Pollpeter MJ; Anderson CG; Burrascano M; Cooney AL; Sinn PL; Rutkowski DT; Raschke WC; McCray PB
    Gene Ther; 2017 Nov; 24(11):742-748. PubMed ID: 28905885
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A.
    Brown BD; Shi CX; Powell S; Hurlbut D; Graham FL; Lillicrap D
    Blood; 2004 Feb; 103(3):804-10. PubMed ID: 14512318
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adenovirus-mediated factor VIII gene expression results in attenuated anti-factor VIII-specific immunity in hemophilia A mice compared with factor VIII protein infusion.
    Bristol JA; Gallo-Penn A; Andrews J; Idamakanti N; Kaleko M; Connelly S
    Hum Gene Ther; 2001 Sep; 12(13):1651-61. PubMed ID: 11535168
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Novel Platform for Immune Tolerance Induction in Hemophilia A Mice.
    Merlin S; Cannizzo ES; Borroni E; Bruscaggin V; Schinco P; Tulalamba W; Chuah MK; Arruda VR; VandenDriessche T; Prat M; Valente G; Follenzi A
    Mol Ther; 2017 Aug; 25(8):1815-1830. PubMed ID: 28552407
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs.
    Jiang H; Lillicrap D; Patarroyo-White S; Liu T; Qian X; Scallan CD; Powell S; Keller T; McMurray M; Labelle A; Nagy D; Vargas JA; Zhou S; Couto LB; Pierce GF
    Blood; 2006 Jul; 108(1):107-15. PubMed ID: 16522813
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The canine factor VIII 3'-untranslated region and a concatemeric hepatocyte nuclear factor 1 regulatory element enhance factor VIII transgene expression in vivo.
    Notley C; Killoran A; Cameron C; Wynd K; Hough C; Lillicrap D
    Hum Gene Ther; 2002 Sep; 13(13):1583-93. PubMed ID: 12228013
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A microRNA-regulated and GP64-pseudotyped lentiviral vector mediates stable expression of FVIII in a murine model of Hemophilia A.
    Matsui H; Hegadorn C; Ozelo M; Burnett E; Tuttle A; Labelle A; McCray PB; Naldini L; Brown B; Hough C; Lillicrap D
    Mol Ther; 2011 Apr; 19(4):723-30. PubMed ID: 21285959
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gene Delivery of Activated Factor VII Using Alternative Adeno-Associated Virus Serotype Improves Hemostasis in Hemophiliac Mice with FVIII Inhibitors and Adeno-Associated Virus Neutralizing Antibodies.
    Sun J; Hua B; Chen X; Samulski RJ; Li C
    Hum Gene Ther; 2017 Aug; 28(8):654-666. PubMed ID: 28478688
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gene therapy for hemophilia.
    Lynch CM
    Curr Opin Mol Ther; 1999 Aug; 1(4):493-9. PubMed ID: 11713765
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Delivery of full-length factor VIII using a piggyBac transposon vector to correct a mouse model of hemophilia A.
    Matsui H; Fujimoto N; Sasakawa N; Ohinata Y; Shima M; Yamanaka S; Sugimoto M; Hotta A
    PLoS One; 2014; 9(8):e104957. PubMed ID: 25126862
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intraosseous delivery of lentiviral vectors targeting factor VIII expression in platelets corrects murine hemophilia A.
    Wang X; Shin SC; Chiang AF; Khan I; Pan D; Rawlings DJ; Miao CH
    Mol Ther; 2015 Apr; 23(4):617-26. PubMed ID: 25655313
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vivo evaluation of an adenoviral vector encoding canine factor VIII: high-level, sustained expression in hemophiliac mice.
    Gallo-Penn AM; Shirley PS; Andrews JL; Kayda DB; Pinkstaff AM; Kaloss M; Tinlin S; Cameron C; Notley C; Hough C; Lillicrap D; Kaleko M; Connelly S
    Hum Gene Ther; 1999 Jul; 10(11):1791-802. PubMed ID: 10446919
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sustained high-level expression of full-length human factor VIII and restoration of clotting activity in hemophilic mice using a minimal adenovirus vector.
    Balagué C; Zhou J; Dai Y; Alemany R; Josephs SF; Andreason G; Hariharan M; Sethi E; Prokopenko E; Jan HY; Lou YC; Hubert-Leslie D; Ruiz L; Zhang WW
    Blood; 2000 Feb; 95(3):820-8. PubMed ID: 10648392
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gene Therapy with BMN 270 Results in Therapeutic Levels of FVIII in Mice and Primates and Normalization of Bleeding in Hemophilic Mice.
    Bunting S; Zhang L; Xie L; Bullens S; Mahimkar R; Fong S; Sandza K; Harmon D; Yates B; Handyside B; Sihn CR; Galicia N; Tsuruda L; O'Neill CA; Bagri A; Colosi P; Long S; Vehar G; Carter B
    Mol Ther; 2018 Feb; 26(2):496-509. PubMed ID: 29292164
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factors influencing therapeutic efficacy and the host immune response to helper-dependent adenoviral gene therapy in hemophilia A mice.
    Brown BD; Shi CX; Rawle FE; Tinlin S; McKinven A; Hough C; Graham FL; Lillicrap D
    J Thromb Haemost; 2004 Jan; 2(1):111-8. PubMed ID: 14717974
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FVIII expression by its native promoter sustains long-term correction avoiding immune response in hemophilic mice.
    Merlin S; FamĂ  R; Borroni E; Zanolini D; Bruscaggin V; Zucchelli S; Follenzi A
    Blood Adv; 2019 Mar; 3(5):825-838. PubMed ID: 30862611
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Immune Response to the fVIII Gene Therapy in Preclinical Models.
    Patel SR; Lundgren TS; Spencer HT; Doering CB
    Front Immunol; 2020; 11():494. PubMed ID: 32351497
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hematopoietic stem cells encoding porcine factor VIII induce pro-coagulant activity in hemophilia A mice with pre-existing factor VIII immunity.
    Doering CB; Gangadharan B; Dukart HZ; Spencer HT
    Mol Ther; 2007 Jun; 15(6):1093-9. PubMed ID: 17387335
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy.
    Connelly S; Andrews JL; Gallo AM; Kayda DB; Qian J; Hoyer L; Kadan MJ; Gorziglia MI; Trapnell BC; McClelland A; Kaleko M
    Blood; 1998 May; 91(9):3273-81. PubMed ID: 9558383
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of improved factor VIII molecules and new gene transfer approaches for hemophilia A.
    Saenko EL; Ananyeva NM; Moayeri M; Ramezani A; Hawley RG
    Curr Gene Ther; 2003 Feb; 3(1):27-41. PubMed ID: 12553533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.